흡입 마취제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Inhalation Anesthesia Market size is expected to reach USD 5.50 Billion in 2034 from USD 2.41 Billion (2025) growing at a CAGR of 9.59% during 2026-2034.

The global inhalation anesthesia market has grown as surgical procedures become more advanced and widely available. Inhalation anesthesia involves the use of anesthetic gases delivered through breathing systems to induce and maintain unconsciousness during surgery. These anesthetics are commonly used in hospitals and surgical centers for procedures requiring general anesthesia.

Market growth is driven by the increasing number of surgeries performed worldwide and the expansion of healthcare infrastructure. Inhalation anesthetics provide rapid onset and controlled sedation, making them suitable for various medical procedures. Improvements in anesthesia delivery systems and patient monitoring technologies have also enhanced safety and effectiveness.

The future outlook for the inhalation anesthesia market remains promising as surgical techniques and healthcare services continue to advance. Research into new anesthetic formulations may improve patient safety and recovery times. Expanding access to surgical care in developing regions is also expected to increase demand. As healthcare systems continue to grow, inhalation anesthesia will remain a critical component of modern surgical practice.

MARKET SEGMENTATION

By Drug

• Sevoflurane
• Desflurane
• Isoflurane
• Others

By Application

• Induction
• Maintenance

By End-Use

• Hospitals
• Ambulatory Surgical Centers
• Others

COMPANIES PROFILED

• AbbVie Inc, Baxter International Inc, Dechra Pharmaceuticals PLC Halocarbon Life Sciences LLC, Fresenius Kabi AG Fresenius SE Co KGaA, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co Ltd, Lunan Pharmaceutical Group Co Ltd, Merck KGaA, Piramal Enterprises Limited, Troikaa Pharmaceuticals Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INHALATION ANESTHESIA MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Sevoflurane Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Desflurane Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Isoflurane Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INHALATION ANESTHESIA MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Induction Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Maintenance Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INHALATION ANESTHESIA MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INHALATION ANESTHESIA MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL INHALATION ANESTHESIA INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 Baxter International Inc
  • 9.2.3 Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC)
  • 9.2.4 Fresenius Kabi AG (Fresenius SE & Co. KGaA)
  • 9.2.5 Hikma Pharmaceuticals PLC
  • 9.2.6 Jiangsu Hengrui Medicine Co. Ltd
  • 9.2.7 Lunan Pharmaceutical Group Co. Ltd
  • 9.2.8 Merck KGaA
  • 9.2.9 Piramal Enterprises Limited
  • 9.2.10 Troikaa Pharmaceuticals Ltd